SVB’s collapse had limited impact on biopharmas — but a broader financial crisis could change the landscape

Although many pharma and biotech companies had deposits at the failed bank, most have reported little to no exposure.

By Michael Gibney • March 21, 2023

Changing the channel from TV to the pharmacy boosts DTC ROI

While a TV spot still has its allure, the level of engagement provided through the pharmacy channel is more than a little compelling.

By Heather Campbell, VP Marketing, Adheris Health • March 20, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back

A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.

By Michael Gibney • March 16, 2023

In the fallout from Aduhelm, Biogen’s leadership shakeup continues

The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.

By Karissa Waddick • March 16, 2023

The PharmaVoice 100 — Who makes the cut

What we’re looking for in each new class of honorees.

By Meagan Parrish • March 15, 2023

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.

By Michael Gibney • March 14, 2023

Biden doubles down on drug pricing in 2024 budget — but boosts R&D

The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.

By Karissa Waddick • March 13, 2023

Across therapy areas, GoodRx’s POS rebates improve access and affordability for cash-paying patients

Across therapy areas, GoodRx Assist is a proven point-of-sale rebate program for cash-paying patients.

March 13, 2023

IQVIA’s OG of data analytics on the latest clinical trial trends

IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

By Taren Grom • March 10, 2023

Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

By Michael Gibney • March 9, 2023

Targeting the new ‘Golden Girls’

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

By Taren Grom • March 8, 2023

Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?

The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?

By Michael Gibney • March 7, 2023

3 keys to good storytelling in pharma

The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

By Alexandra Pecci • March 7, 2023

Why layoffs are not the answer to biopharma’s troubled market

As companies look to cut costs, an EY analyst urges them to consider not cutting staff.

By Kelly Bilodeau • March 6, 2023

FDA ups generics and biosimilar approvals for a shot at lower drug costs

As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022. 

By Karissa Waddick • March 6, 2023

Biosimilar insights to help marketers navigate the year ahead

Bracing for biosimilars? Learn how biosimilar launches differ from traditional biologics.

March 6, 2023

PharmaVoice 100 honorees: Where are they now?

How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

By Taren Grom , Karissa Waddick • March 3, 2023

Do R&D costs justify the price of drugs? Nope, new study says

A BMJ study found that spending on drug sales vastly outstripped spending on drug development.

By Alexandra Pecci • March 1, 2023

Woman of the Week: Denali Therapeutics’ Cindy Dunkle

As chief people officer, Dunkle is harnessing the company’s unique culture to foster innovation.

By Taren Grom • March 1, 2023

Reata’s stock plummets amid sudden FDA neuro office shakeup

The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.

By Karissa Waddick • Feb. 28, 2023

As clinical trials face a hiring crunch, here’s how research organizations can pivot

Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.

By Kelly Bilodeau • Feb. 27, 2023

Why patient care is a public affair

The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

By Taren Grom • Feb. 23, 2023

Why FDA’s approach to orphan drug exclusivity is ripe for more legal challenges

Despite a court ruling, the FDA is sticking to its narrow orphan drug exclusivity approach. But confusion remains over the policy’s future. 

By Karissa Waddick • Feb. 23, 2023

Woman of the Week: Alltrna’s Michelle Werner

The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.

By Taren Grom • Feb. 22, 2023